PLA2G7

Across TCGA pan-cancer cohorts, PLA2G7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLA2G7 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLA2G7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLA2G7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PLA2G7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.897	0.583	<.001	15	view →
LUAD	OS	Tertile	All	0.723	0.905	.026	8	view →
CCRCC	OS	Median	All	1.000	0.924	.041	3	view →
PDAC	DFS	Median	IV	0.276	0.766	.047	3	view →
GBM	DFS	Median	All	0.438	0.212	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLA2G7–HNSC (OS)

Open the HNSC breakdown →